Skip to main content
Clinical Trials/NCT06761742
NCT06761742
Completed
Not Applicable

An Artificial Intelligence Model for Accurate Diagnosis of Renal Tumors Based on Multi-phase Contrast-enhanced CT and Laboratory Tests: A Model Development and Multi-center Evaluation Study

RenJi Hospital1 site in 1 country1,922 target enrollmentJanuary 1, 2024
ConditionsRenal Tumors

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Renal Tumors
Sponsor
RenJi Hospital
Enrollment
1922
Locations
1
Primary Endpoint
postoperative pathological report
Status
Completed
Last Updated
last year

Overview

Brief Summary

This multi-center retrospective study aims to develop a multimodal artificial intelligence diagnostic model using preoperative contrast-enhanced CT images and routine laboratory parameters from patients with renal tumors. The model is designed to assist clinicians in accurately predicting the pathological subtypes of renal tumors preoperatively, enabling detailed diagnoses and advancing precision medicine.

Registry
clinicaltrials.gov
Start Date
January 1, 2024
End Date
December 1, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Underwent renal tumor resection with a complete postoperative pathological report, and the pathological diagnosis is one of the following types: clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, renal angiomyolipoma, or renal oncocytoma.
  • Complete and available four-phase contrast-enhanced CT scans prior to surgery.
  • Complete and available routine laboratory test results prior to surgery.

Exclusion Criteria

  • Incomplete CT data or poor image quality that affects diagnostic analysis.
  • A time interval of more than three months between imaging or laboratory testing and pathological diagnosis.
  • Patients diagnosed with fat-rich renal angiomyolipoma (AML).
  • Pathological diagnosis indicating the coexistence of two or more pathological types of renal tumors.

Outcomes

Primary Outcomes

postoperative pathological report

Time Frame: From the time of surgery to the release of the postoperative pathological report (typically within 2 weeks post-surgery).

Study Sites (1)

Loading locations...

Similar Trials